Company / Free Cash Flow
Cytek Biosciences, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$8.8M
FY2025
5-year range
-$22.0M / $21.9M
FY2021-FY2025
Trend
-140.1%
vs FY2024
Sector context
#120 of 151
Health Care
What the data says
Cytek Biosciences, Inc.'s free cash flow of -$9M is lower than 79% of companies in the Health Care sector (FY2025). Declined from $633,000 to -$9M over the past 2 years.
Based on SEC 10-K filings.
-$9M in FY2025.
Declined from $633,000 to -$9M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 151This company -$8.8M Sector average $779.8M
▼
-101.1% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 140.1% year-over-year.
- Ranks #120 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.8M | -140.1% |
| FY2024 | $21.9M | +3352.4% |
| FY2023 | $633.0K | +102.9% |
| FY2022 | -$22.0M | -261.5% |
| FY2021 | $13.6M | +0.0% |
| FY2020 | $13.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026